Kumbla D K, Kumar S, Reddy Y V, Trailokya A, Naik M
Consultant Clinical & Interventional Cardiologist, Jupiter Hospital, Thane, India.
Consultant Cardiologist, AMRI Hospital, Kolkata, India.
Indian Heart J. 2014 May-Jun;66(3):340-4. doi: 10.1016/j.ihj.2014.05.002.
Hypertension is a global health problem. Multiple classes of drugs including angiotensin receptor blockers (ARBs) are available for the treatment of hypertension. Olmesartan is a relatively newer ARB used in hypertension management.
To assess the efficacy and safety of WIN-BP (Olmesartan 20 mg/40 mg) tablet in Indian patients with hypertension.
An open label, non-comparative, multi-centric, real world post marketing observational study included Indian adult hypertensive patients who were treated with olmesartan 20 mg/40 mg tablet once daily for six months. The primary outcome was reduction of systolic blood pressure (SBP) to <140 mmHg and diastolic BP (DBP) to <90 mmHg at 3 and 6 months after initiation of treatment with olmesartan. All reported adverse events were recorded.
A total of 8940 patients were enrolled in this study. Baseline SBP of 164 mmHg was reduced to 153, 145, 134 and 130 mmHg at the end of 15 days, 1, 3 and 6 months respectively. Similarly, baseline DBP of 100 mmHg was reduced to 93, 89, 84 and 82 mmHg at the end of 15 days, 1, 3 and 6 months respectively. The reduction in both systolic and diastolic blood pressure from day 15 to month 6 was statistically significant (p < 0.0001) with olmesartan treatment. The percentage of responders for both systolic and diastolic blood pressure increased consistently from day 15 to month 6. Only 0.08% patients reported the adverse events. No serious adverse event was reported in the study.
Olmesartan 20 mg/40 mg is effective and well tolerated without any serious adverse events in patients with hypertension.
高血压是一个全球性的健康问题。包括血管紧张素受体阻滞剂（ARB）在内的多种药物可用于治疗高血压。奥美沙坦是一种相对较新的用于高血压管理的ARB。
评估WIN-BP（奥美沙坦20毫克/40毫克）片剂对印度高血压患者的疗效和安全性。
一项开放标签、非对照、多中心、真实世界上市后观察性研究，纳入印度成年高血压患者，他们每天服用一次奥美沙坦20毫克/40毫克片剂，持续六个月。主要结局是在开始使用奥美沙坦治疗3个月和6个月时，收缩压（SBP）降至<140 mmHg，舒张压（DBP）降至<90 mmHg。记录所有报告的不良事件。
本研究共纳入8940例患者。基线收缩压164 mmHg在第15天、1个月、3个月和6个月末分别降至153 mmHg、145 mmHg、134 mmHg和130 mmHg。同样，基线舒张压100 mmHg在第15天、1个月、3个月和6个月末分别降至93 mmHg、89 mmHg、84 mmHg和82 mmHg。奥美沙坦治疗后，从第15天到第6个月，收缩压和舒张压均显著降低（p<0.0001）。从第15天到第6个月，收缩压和舒张压的达标患者百分比持续增加。仅0.08%的患者报告了不良事件。该研究未报告严重不良事件。
奥美沙坦20毫克/40毫克对高血压患者有效且耐受性良好，未发生任何严重不良事件。
